米非司酮治疗子宫肌瘤的剂量探讨

目的:探讨米非司酮治疗子宫肌瘤的剂量。方法:将81例确诊为子宫肌瘤的患者随机分成3组,Ⅰ组口服米非司酮25mg/d×3个月;Ⅱ组口服米非司酮12.5mg/d×3个月;Ⅲ组口服米非司酮6.25mg/d×3个月。结果:用药过程中3组肌瘤均有不同程度的缩小,贫血得以纠正,围绝经期可致绝经。结论:12.5mg/d剂量米非司酮连服3个月为一疗程的治疗方案,副反应轻,疗效与25mg/d组无显著差异,费用可以减少50％。     

238例复治肺结核病人耐药状况分析

目的 了解复治肺结核病人形成原因和耐药状况，分析结核病控制策略的效果。方法 分析1999年湖北省耐药监测入选238例复治涂阳培阳病例既往病史和耐药状况；药敏试验采用比例法，培养基中药物浓度分别为S 4μg/ml、H 0．2μg/ml、R 40μg/ml和E 2μg/ml；结果 总耐药率为44．5％，耐多药率为21．8％，在综合医院、乡镇卫生院和结防专业机构治疗造成的耐药率和耐多药率(含H和R)分别为56．4％、31．3％、46．3％和30．8％、15．0％、20．8％。结论 治疗不规范是导致耐药率和耐多药率升高的原因，建议加强结核病人归口、化疗和全程督导管理，进一步完善结核病控制策略，减少复治病例和耐药的产生。     

Human Herpesvirus 6 in Bronchalveolar Lavage Fluid after Lung Transplantation: A Risk Factor for Bronchiolitis Obliterans Syndrome?

Bronchiolitis obliterans syndrome (BOS) is the limiting factor to long-term survival after lung transplantation. Previous studies suggested respiratory viral tract infections are associated with the development of BOS. To identify the impact of virus detection in bronchoalveolar lavage (BAL) fluid, we analyzed BAL samples from 87 consecutive lung transplant recipients for human herpesvirus (HHV)-6, Epstein-Barr virus, Herpes simplex virus 1/2, Cytomegalovirus, respiratory syncytical virus and adenovirus by PCR. Acute rejection, BOS and death were recorded for a mean follow-up time of 3.27 +/- 0.47 years. Results of PCR analysis and other potential risk factors were entered into a Cox regression analysis of BOS predictors and death. Only acute rejection was a distinct risk factor for BOS of all stages, death and death from BOS. HHV-6 was detected in 20 patients. Univariate and multivariate analysis revealed that HHV-6 was associated with an increased risk to develop BOS > orb = stage 1 and death, separate from the risk attributable to acute rejection. Identification of HHV-6 DNA in BAL fluid is a potential risk factor for BOS. Our results warrant further studies to elucidate a possible causal link between HHV-6 and BOS.